S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern

Esperion Therapeutics (ESPR) Earnings Date, Estimates & Call Transcripts

$2.14
-0.17 (-7.36%)
(As of 04/12/2024 08:51 PM ET)

Earnings Summary

Upcoming
Earnings Date
May. 14Estimated
Actual EPS
(Feb. 27)
-$0.50 Beat By $0.03
Consensus EPS
(Feb. 27)
-$0.53
Skip Charts & View Estimated and Actual Earnings Data

ESPR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ESPR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Esperion Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20243($0.38)($0.24)($0.29)
Q2 20243($0.25)($0.21)($0.24)
Q3 20243($0.25)($0.11)($0.18)
Q4 20243($0.24)($0.05)($0.15)
FY 202412($1.12)($0.61)($0.85)
Q1 20251($0.14)($0.14)($0.14)
Q2 20251($0.01)($0.01)($0.01)
Q3 20251$0.03$0.03$0.03
Q4 20251$0.17$0.17$0.17
FY 20254$0.05$0.05$0.05
Q1 20261$0.89$0.89$0.89

ESPR Earnings Date and Information

Esperion Therapeutics last announced its quarterly earnings data on February 27th, 2024. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.03. The firm earned $32.25 million during the quarter, compared to the consensus estimate of $26.84 million. Esperion Therapeutics has generated ($2.12) earnings per share over the last year (($2.12) diluted earnings per share). Earnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.68) to $0.31 per share. Esperion Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off prior year's report dates.

Esperion Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/14/2024
Estimated)
------- 
2/27/2024Q4 2023($0.53)($0.50)+$0.03($0.50)$26.84 million$32.25 million    
11/7/2023Q3 2023($0.42)($0.37)+$0.05($0.37)$30.84 million$33.97 million    
8/1/2023Q2 2023($0.61)($0.46)+$0.15($0.46)$24.64 million$25.79 million    
5/9/2023Q1 2023($0.65)($0.79)($0.14)($0.79)$21.97 million$24.30 million    
2/21/2023Q4 2022($0.87)($0.76)+$0.11($0.76)$20.60 million$18.18 million    
11/1/2022Q3 2022($0.93)($0.81)+$0.12($0.81)$19.83 million$18.98 million
8/2/2022Q2 2022($0.95)($1.05)($0.10)($1.05)$18.62 million$18.80 million    
5/3/2022Q1 2022($0.96)($0.93)+$0.03($0.93)$15.41 million$18.84 million    
2/22/2022Q4 2021($2.32)($1.77)+$0.55($1.77)$14.48 million$15.40 million    
11/2/2021Q3 2021($2.86)($2.62)+$0.24($2.62)$12.31 million$14.41 million    
8/3/2021Q2 2021($1.82)($1.67)+$0.15($1.67)$42.16 million$40.70 million    
5/4/2021Q1 2021($2.08)($3.50)($1.42)($3.50)$34.28 million$8.00 million  

Esperion Therapeutics Earnings - Frequently Asked Questions

When is Esperion Therapeutics's earnings date?

Esperion Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off last year's report dates. Learn more on ESPR's earnings history.

Did Esperion Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Esperion Therapeutics (NASDAQ:ESPR) reported ($0.50) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.53) by $0.03. Learn more on analysts' earnings estimate vs. ESPR's actual earnings.

How can I listen to Esperion Therapeutics's earnings conference call?

The conference call for Esperion Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Esperion Therapeutics's conference call transcript?

The conference call transcript for Esperion Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Esperion Therapeutics generate each year?

Esperion Therapeutics (NASDAQ:ESPR) has a recorded annual revenue of $116.33 million.

How much profit does Esperion Therapeutics generate each year?

Esperion Therapeutics (NASDAQ:ESPR) has a recorded net income of -$209.25 million. ESPR has generated -$2.12 earnings per share over the last four quarters.

What is Esperion Therapeutics's EPS forecast for next year?

Esperion Therapeutics's earnings are expected to grow from ($0.68) per share to $0.31 per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:ESPR) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners